Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Kivu Bioscience Inc.
Hoffmann-La Roche
Bayer
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
University of Florida
Essen Biotech
MacroGenics
Avacta Life Sciences Ltd
Institut Curie
Solve Therapeutics
Perspective Therapeutics
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
Tanabe Pharma America, Inc.
HiFiBiO Therapeutics
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Hadassah Medical Organization
Institut Bergonié
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Institut Claudius Regaud
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
University of California, Irvine
Cancer Research UK
University Health Network, Toronto
Instituto do Cancer do Estado de São Paulo
Elevation Oncology
University of South Florida
Stanford University
Mayo Clinic
Stanford University
Cybrexa Therapeutics
Medigene AG
Cyteir Therapeutics, Inc.
Shanghai PerHum Therapeutics Co., Ltd.
Brown University
Washington University School of Medicine
NantCell, Inc.
Xencor, Inc.
Prelude Therapeutics
Second Affiliated Hospital of Guangzhou Medical University